FR2316964A1 - Medicament contenant, a titre de principe actif, un produit a base de polysaccharides, notamment obtenu a partir de lipopolysaccharides bacteriens - Google Patents

Medicament contenant, a titre de principe actif, un produit a base de polysaccharides, notamment obtenu a partir de lipopolysaccharides bacteriens

Info

Publication number
FR2316964A1
FR2316964A1 FR7522011A FR7522011A FR2316964A1 FR 2316964 A1 FR2316964 A1 FR 2316964A1 FR 7522011 A FR7522011 A FR 7522011A FR 7522011 A FR7522011 A FR 7522011A FR 2316964 A1 FR2316964 A1 FR 2316964A1
Authority
FR
France
Prior art keywords
gram
marcescens
radiation
compsns
prepd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7522011A
Other languages
English (en)
Other versions
FR2316964B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Priority to FR7522011A priority Critical patent/FR2316964A1/fr
Publication of FR2316964A1 publication Critical patent/FR2316964A1/fr
Application granted granted Critical
Publication of FR2316964B1 publication Critical patent/FR2316964B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/425—Serratia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Materials Engineering (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
FR7522011A 1975-07-11 1975-07-11 Medicament contenant, a titre de principe actif, un produit a base de polysaccharides, notamment obtenu a partir de lipopolysaccharides bacteriens Granted FR2316964A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7522011A FR2316964A1 (fr) 1975-07-11 1975-07-11 Medicament contenant, a titre de principe actif, un produit a base de polysaccharides, notamment obtenu a partir de lipopolysaccharides bacteriens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7522011A FR2316964A1 (fr) 1975-07-11 1975-07-11 Medicament contenant, a titre de principe actif, un produit a base de polysaccharides, notamment obtenu a partir de lipopolysaccharides bacteriens

Publications (2)

Publication Number Publication Date
FR2316964A1 true FR2316964A1 (fr) 1977-02-04
FR2316964B1 FR2316964B1 (fr) 1978-12-22

Family

ID=9157890

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7522011A Granted FR2316964A1 (fr) 1975-07-11 1975-07-11 Medicament contenant, a titre de principe actif, un produit a base de polysaccharides, notamment obtenu a partir de lipopolysaccharides bacteriens

Country Status (1)

Country Link
FR (1) FR2316964A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2444464A1 (fr) * 1978-12-19 1980-07-18 Fabre Sa Pierre Proteoglycanes bacteriens purifies, procede pour leur preparation et vaccin les contenant
WO1986005687A1 (fr) * 1985-04-03 1986-10-09 Wisconsin Alumni Research Foundation Procede de prevention de maladies causees chez les mammiferes par l'endotoxine gram-negatif
EP0528635A1 (fr) * 1991-08-16 1993-02-24 Merck & Co. Inc. Procédé pour convertir des polysaccharides bactériens capsulaires contenant des lipides en des polysaccharides exempts de lipides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH83A (fr) * 1888-11-17 1889-01-10 Fontainemelon Horlogerie Perfectionnements apportés à la construction des montres de tous calibres

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH83A (fr) * 1888-11-17 1889-01-10 Fontainemelon Horlogerie Perfectionnements apportés à la construction des montres de tous calibres

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
26140J 1975 CITE : J. IMMUNOL. 1975, 115 1 , 199-203) *
CHEMICAL ABSTRACTS 75 30953D 1971 CITE : STRAHLENTHERAPIE 1971, 141 2 , 214-20 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2444464A1 (fr) * 1978-12-19 1980-07-18 Fabre Sa Pierre Proteoglycanes bacteriens purifies, procede pour leur preparation et vaccin les contenant
EP0013851A1 (fr) * 1978-12-19 1980-08-06 Pierre Fabre S.A. Protéoglycanes bactériens purifiés, procédé pour leur préparation et vaccin les contenant
WO1986005687A1 (fr) * 1985-04-03 1986-10-09 Wisconsin Alumni Research Foundation Procede de prevention de maladies causees chez les mammiferes par l'endotoxine gram-negatif
EP0528635A1 (fr) * 1991-08-16 1993-02-24 Merck & Co. Inc. Procédé pour convertir des polysaccharides bactériens capsulaires contenant des lipides en des polysaccharides exempts de lipides
WO1993004183A1 (fr) * 1991-08-16 1993-03-04 Merck & Co., Inc. Procede de conversion d'un polysaccharide capsulaire bacterien contenant des lipides en polysaccharide sans lipide

Also Published As

Publication number Publication date
FR2316964B1 (fr) 1978-12-22

Similar Documents

Publication Publication Date Title
Taliaferro et al. Effect of X-rays on immunity: a review
Henshaw et al. The biologic effects of pile radiations
AU553185B2 (en) Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them
AU543201B2 (en) Vaccinal complex containing a specific antigen and vaccine containing it
Benacerraf Influence of irradiation on resistance to infection
PT88590A (pt) Process for preparing an inactivated vaccine composition
FR2527444B1 (fr) Composition therapeutique contenant une endotoxine raffinee debarrassee de sa toxicite
ES433613A1 (es) Procedimiento para esterilizar equipos medicos o quirurgi- cos.
FR2316964A1 (fr) Medicament contenant, a titre de principe actif, un produit a base de polysaccharides, notamment obtenu a partir de lipopolysaccharides bacteriens
SE8203274L (sv) Antracykliner och forfarande for deras framstellning
UA15930A (uk) Спосіб одержаhhя похідhих тієhопіраhу
US3093489A (en) Prevention of off-flavors in radiationsterilized beef
Durban et al. Resistance of spores of Clostridium botulinum 33A to combinations of ultraviolet and gamma rays
Reid et al. The influence of X-radiation on mortality following thermal flash burns: the site of tissue injury as a factor determining the type of invading bacteria
ES442505A1 (es) Procedimiento de preparacion de la 4-0-n2',6'-diamino-2',3',6' - tridesoxi-alfa, d-ribohexopiranosiln6-0 - n3" - metila-mino-3",4",6"tridesoxi alfa,d-xilohexopiranosiln2-desoxies- treptamina.
Snipes et al. Radiation damage to Artemia cysts: effects of water vapor
Waggoner et al. Crown gall suppression by ionizing radiation
AU2060783A (en) Morphine-vitamin b12 analgesic treatment
ES8406501A1 (es) Un metodo para la preparacion de un extracto glicosidico.
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok
AU558008B2 (en) Ozone inactivated organisms as vaccines
Silverman et al. Bacteriological Studies on Mice Exposed to Supralethal Doses of Ionizing Radiations: II. Fast Neutron and X-Radiation from Laboratory Sources
IT8121484A0 (it) Estratto da piante del genere epimedium, procedimento per lapreparazione di detto estratto, agente immunostimolante che comprende detto estratto come componente efficace e immunoterapia mediante l'impiego di detto estratto.
Stewart et al. Effects of continuous irradiation of mice on the immune response to live Listeria monocytogenes
SU546315A1 (ru) Высеивающий аппарат

Legal Events

Date Code Title Description
TP Transmission of property
ST Notification of lapse